

### IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
06990	SKB BIO-B	2023/07/04	2023/07/10	2023/07/11

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit [www.cfsg.com.hk](http://www.cfsg.com.hk) or contact our account executives or customer service officers

### Subscription Details via CASH Securities

Offer Period	2023/06/29 - 2023/07/04
Closing Time for Margin Application	N/A
Subscription Fee	N/A
Days For Margin Financing	N/A
Indicative Interest Rate	N/A

\*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

### Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)

#### Share Offer Highlights

Total Number of Offer Shares:	22,446,100 H Shares (subject to the Over-allotment Option)
-Number of Public Offer Shares:	2,244,700 H Shares (subject to reallocation)
-Number of Placing Shares:	20,201,400 H Shares (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	100 Shares
Offer Price:	HKD 60.60-72.80 per Share
2020 Historical P/E ratio:	-
Sponsor:	Goldman Sachs、CITIC SECURITIES

#### Company Overview

This company is a biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs in oncology, immunology and other therapeutic areas since its incorporation in 2016. It has two ADC drugs as its Core Products, namely, SKB264 and A166. SKB264 is a novel phase 3-stage TROP2 ADC positioned as a late-line monotherapy and part of early-line combination therapies for treating various advanced solid tumors. A166 is a differentiated NDA registration-stage HER2 ADC positioned as a late-line monotherapy to treat advanced HER2+ solid tumors. As of the Latest Practicable Date, it was also developing 12 non-core clinical-stage assets.

For the year ended December 31, 2021 and 2022, the Company's net losses were RMB 889.80mn and RMB 616.10 mn respectively.

#### Source

IPO Prospectus

#### Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
Wealth Management Centre:	1001B, 10/F, Tower 535 Jaffe Road Causeway Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen 2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(86-755) 2216 5888 (86-21) 3227 9888 (86-20) 8981 7463

**Declaration:**

The above information is provided and distributed by CASH Financial Services Group Limited ( "CASH" ). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.